Cybin Inc. (CYBN) has announced promising 12-month efficacy and safety data from its Phase 2 study of CYB003 in patients with major depressive disorder (MDD). The company presented the data during a conference call and webcast on November 18, 2024, and further discussed the findings in a Water Tower Research fireside chat on December 11, 2024.
CYB003 is a proprietary deuterated psilocin analog, designed for intermittent use to achieve long-lasting results in treating mental health conditions. The Phase 2 trial evaluated the efficacy and safety of CYB003 in individuals with MDD.
Sustained Efficacy Data
The 12-month data from the Phase 2 study demonstrated sustained efficacy of CYB003 in reducing depressive symptoms. While specific data points were not detailed in the source articles, the presentation highlighted the potential of CYB003 as a rapid-acting and potentially long-lasting treatment option for MDD.
Phase 3 PARADIGM Program
Cybin has initiated the Phase 3 PARADIGM program to further evaluate CYB003 as an adjunctive treatment for MDD. The program's design, enrollment process, and milestone targets were discussed during the November presentation and December fireside chat. This Phase 3 trial will likely involve a larger patient population and a more rigorous evaluation of CYB003's efficacy and safety compared to the Phase 2 study.
Company Leadership Commentary
Cybin's CEO, Doug Drysdale, and Chief Medical Officer, Amir Inamdar, have been actively involved in presenting the CYB003 data and outlining the company's clinical development strategy. Their participation in events like the Water Tower Research fireside chat underscores Cybin's commitment to transparency and engagement with the investment community.
About Cybin Inc.
Cybin is a neuropsychiatry company focused on developing innovative treatments for mental health conditions. In addition to CYB003, Cybin is also developing CYB004, a deuterated N, N-dimethyltryptamine molecule, for generalized anxiety disorder. The company's research pipeline includes other investigational compounds targeting 5-HT receptors.
